{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:48:28Z","timestamp":1791362908233,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2017J01378"],"award-info":[{"award-number":["2017J01378"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2018J01355"],"award-info":[{"award-number":["2018J01355"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical and Health guidance project of Xiamen","award":["3502Z20214ZD1059"],"award-info":[{"award-number":["3502Z20214ZD1059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The chemokine CXCL1, known as growth-related oncogene \u03b1 (GRO-\u03b1), is a potent chemoattractant and regulator of neutrophils. The purpose of our study was to evaluate the regulatory response of CXCL1 in the serum of patients with systemic lupus erythematosus (SLE) in the active stage of disease and to assess whether it was implicated in the pathogenesis\/inflammatory process in lupus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CXCL1 serum concentrations were examined in 90 SLE patients, 56 other autoimmune diseases (OADs) patients and 100 healthy controls using enzyme-linked immunosorbent methodology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SLE patients exhibited significant increases in serum CXCL1 concentrations [1492.86 (735.47\u20132887.34) pg\/ml] compared with OADs patients [155.88 (10.77\u2013366.78) pg\/ml] and healthy controls [13.58 (8.46\u201337.22) pg\/ml] (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Moreover, the level of CXCL1 decreased as the level of anti-dsDNA IgG decreased after treatment between the anti-dsDNA-positive SLE patients and the anti-dsDNA-negative SLE patients. Additionly, serum CXCL1 concentrations were related to different disease activity levels in SLE and lupus nephritis (LN) and high avidity of IgG ANAs (HA IgG ANAs) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Furthermore, CXCL1 serum concentrations were significantly correlated with the SLE Disease Activity Index(SLEDAI) score, relative avidity index (RAI) of HA IgG ANAs and the levels of anti-dsDNA IgG, CRP, ESR, albumin, C3 and C4.Additionally, Statistical analysis revealed that positivity for IgG ANA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), the presence of HA IgG ANAs (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and the logarithmic level of anti-dsDNA IgG (<jats:italic>p<\/jats:italic>\u2009=\u20090.021) were significantly associated with the logarithmic level of CXCL1 with standard partial regression coefficients (95% CI) of 2.371 (1.734\u20133.009), 1.231 (0.52\u20131.937) and 0.409 (0.062\u20130.755), respectively. Finally, using cutoff points of 1182.17\u00a0pg\/mL and 1500.31\u00a0pg\/mL, serum CXCL1 levels had a similar sensitivity of 76% and specificity of 100% and 75% for the diagnosis of active SLE and LN, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Serum CXCL13 concentrations might represent a potential marker of disease activity in systemic lupus erythematosus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-021-00469-x","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T09:03:55Z","timestamp":1640595835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus"],"prefix":"10.1186","volume":"22","author":[{"given":"Yanli","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoduan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuidi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s10067-020-05040-4","volume":"39","author":"Y Zeng","year":"2020","unstructured":"Zeng Y, Lin Y, Wang X, et al. Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus. Clin Rheumatol. 2020;39:2619\u201329.","journal-title":"Clin Rheumatol"},{"key":"469_CR2","doi-asserted-by":"crossref","unstructured":"2016 ACR\/ARHP annual meeting abstract supplement. Arthritis Rheumatol 2016; 68(S10): 1\u20134550.","DOI":"10.1002\/art.39977"},{"issue":"3","key":"469_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1128\/CMR.4.3.256","volume":"4","author":"MJ Fritzler","year":"1991","unstructured":"Fritzler MJ, Salazar M. Diversity and origin of rheumatologic autoantibodies. Clin Microbiol Rev. 1991;4(3):256\u201369.","journal-title":"Clin Microbiol Rev"},{"key":"469_CR4","doi-asserted-by":"publisher","unstructured":"Zeng Y, Zhang Y, Lin Y, Wang X et al. The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythematosus with disease activity. Clin Exp Med 2021; 1\u20139. https:\/\/doi.org\/10.1007\/s10238-021-00707-x.","DOI":"10.1007\/s10238-021-00707-x"},{"issue":"2","key":"469_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clim.2008.03.516","volume":"128","author":"HA Kim","year":"2008","unstructured":"Kim HA, Jeon JY, Choi GS, et al. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol. 2008;128(2):277\u201383.","journal-title":"Clin Immunol"},{"issue":"7","key":"469_CR6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1681\/ASN.V1271369","volume":"12","author":"GP de Lema","year":"2001","unstructured":"de Lema GP, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001;12(7):1369\u201382.","journal-title":"J Am Soc Nephrol"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.2741\/2927","volume":"13","author":"O Kulkarni","year":"2008","unstructured":"Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front Biosci. 2008;13:3312\u201320.","journal-title":"Front Biosci"},{"issue":"1","key":"469_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/cells9010072","volume":"9","author":"HS Howe","year":"2019","unstructured":"Howe HS, Leung BPL. Anti-cytokine autoantibodies in systemic lupus erythematosus. Cells. 2019;9(1):72.","journal-title":"Cells"},{"issue":"3","key":"469_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jcp.1041290316","volume":"129","author":"A Richmond","year":"1986","unstructured":"Richmond A, Thomas HG. Purification of melanoma growth stimulatory activity. J Cell Physiol. 1986;129(3):375\u201384.","journal-title":"J Cell Physiol"},{"issue":"6","key":"469_CR10","first-page":"RA87","volume":"13","author":"C Bechara","year":"2007","unstructured":"Bechara C, Chai H, Lin PH, Yao Q, Chen C. Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis and other inflammatory conditions. Med Sci Monit. 2007;13(6):RA87\u201390.","journal-title":"Med Sci Monit"},{"issue":"2","key":"469_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cyto.2013.03.016","volume":"62","author":"P Kanapathippillai","year":"2013","unstructured":"Kanapathippillai P, Hedberg A, Fenton CG, Fenton KA. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis. Cytokine. 2013;62(2):244\u201352.","journal-title":"Cytokine"},{"key":"469_CR12","doi-asserted-by":"publisher","first-page":"28997","DOI":"10.1038\/srep28997","volume":"6","author":"H Wang","year":"2016","unstructured":"Wang H, Knight JS, Hodgin JB, et al. Psgl-1 deficiency is protective against stroke in a murine model of lupus. Sci Rep. 2016;6:28997.","journal-title":"Sci Rep"},{"issue":"9","key":"469_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"469_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630\u201340.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"469_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"469_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0961203308100481","volume":"18","author":"C Gordon","year":"2009","unstructured":"Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257\u201363.","journal-title":"Lupus"},{"issue":"7","key":"469_CR17","first-page":"1524","volume":"30","author":"S Furuse","year":"2003","unstructured":"Furuse S, Fujii H, Kaburagi Y, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol. 2003;30(7):1524\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"469_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00418-012-1035-z","volume":"139","author":"S Lisi","year":"2013","unstructured":"Lisi S, Sisto M, Lofrumento DD, D\u2019Amore M, De Lucro R, Ribatti D. A potential role of the GRO-\u03b1\/CXCR2 system in Sj\u00f6gren\u2019s syndrome: regulatory effects of pro-inflammatory cytokines. Histochem Cell Biol. 2013;139(2):371\u20139.","journal-title":"Histochem Cell Biol"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2741\/2731","volume":"13","author":"BH Rovin","year":"2008","unstructured":"Rovin BH. The chemokine network in systemic lupus erythematous nephritis. Front Biosci. 2008;13:904\u201322.","journal-title":"Front Biosci"},{"issue":"5","key":"469_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","volume":"16","author":"SR Greisen","year":"2014","unstructured":"Greisen SR, Schelde KK, Rasmussen TK, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic \u201cwindow of opportunity.\u201d Arthritis Res Ther. 2014;16(5):434\u201343.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"469_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semarthrit.2007.09.005","volume":"38","author":"S-S Lee","year":"2008","unstructured":"Lee S-S, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum. 2008;38(1):41\u201354.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"469_CR22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3899\/jrheum.091028","volume":"37","author":"J Yip","year":"2010","unstructured":"Yip J, Aghdassi E, Su J, et al. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus. J Rheumatol. 2010;37(8):1667\u201372.","journal-title":"J Rheumatol"},{"key":"469_CR23","doi-asserted-by":"crossref","unstructured":"The 10th International Congress on SLE April 18\u201321 2013, Buenos Aires, Argentina Oral Presentations. Lupus 2013; 22(1_suppl): 1\u2013196.","DOI":"10.1177\/0961203313476777"},{"issue":"12","key":"469_CR24","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1681\/ASN.2015101077","volume":"27","author":"JH Riedel","year":"2016","unstructured":"Riedel JH, Paust HJ, Krohn S, et al. IL-17F promotes tissue injury in autoimmune kidney diseases. J Am Soc Nephrol. 2016;27(12):3666\u201377.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"469_CR25","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2006060634","volume":"18","author":"HJ Brown","year":"2007","unstructured":"Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson MG. Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol. 2007;18(6):1732\u20139.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-021-00469-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T09:09:28Z","timestamp":1640596168000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-021-00469-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1186\/s12865-021-00469-x","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"19 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of Zhongshan Hospital, Medical College Xiamen University, and conforms to the ethical guidelines of the Declaration of Helsinki. Requirement for individual patient consent forms was waived due to the retrospective, observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}